Trials / Completed
CompletedNCT00311402
JASAP: Japanese Aggrenox Stroke Prevention vs. Aspirin Programme
JASAP: Japanese Aggrenox Stroke Prevention vs. Aspirin Programme, Phase III Study to Compare the Preventive Effect of Recurrent Brain Infarction and Safety of Aggrenox (Combination Drug Containing Sustained-release Dipyridamole 200 mg/Acetylsalicylic Acid 25 mg) Twice Daily vs. Acetylsalicylic Acid 81 mg Once Daily
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,295 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
Phase III study to compare the preventive effect of recurrent brain infarction and safety of Aggrenox (combination drug containing sustained-release dipyridamole 200 mg/acetylsalicylic acid 25 mg) twice daily vs. acetylsalicylic acid 81 mg once daily
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Aggrenox capsule | extended-release dipyridamole 200 mg plus ASA 50 mg in a capsule, 2 capsules twice daily |
| OTHER | Acetylsalicylic Acid (ASA) | Acetylsalicylic Acid (ASA) 81 mg, 1 tablet once daily |
Timeline
- Start date
- 2006-04-01
- Primary completion
- 2009-03-01
- First posted
- 2006-04-06
- Last updated
- 2014-02-14
- Results posted
- 2010-03-11
Locations
151 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT00311402. Inclusion in this directory is not an endorsement.